Overview of thrombopoietic agents in the treatment of thrombocytopenia

Clinical Lymphoma and Myeloma

Volumn 8, Issue 1, 2008, Pages 33-43

  Kobos, Rachel ^a   Bussel, James B ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

AKR 501; AMG 531; Eltrombopag; Interleukin 11; Megakaryocytes

Indexed keywords

AKR 501; CARBOPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DIMETHOATE; DOXORUBICIN; ELTROMBOPAG; ETOPOSIDE; FLUOROURACIL; IDARUBICIN; INTERFERON; INTERLEUKIN 11; LGD 4665; MITOXANTRONE; NEUTRALIZING ANTIBODY; NIP 004; PACLITAXEL; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; REMIPLISTIM; SB 559448; UNCLASSIFIED DRUG;

ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; BLOODY DIARRHEA; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; CONTUSION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; FATIGUE; FEMALE GENITAL TRACT TUMOR; GINGIVA BLEEDING; HEADACHE; HEART ATRIUM FIBRILLATION; HEMATOPOIETIC STEM CELL; HEMORRHOID; HEPATITIS C; HUMAN; LUNG CANCER; MEGAKARYOCYTE; MENORRHAGIA; MULTIPLE CYCLE TREATMENT; MYOSITIS; NEOPLASM; NONHUMAN; PERIPHERAL EDEMA; REVIEW; SARCOMA; SOLID TUMOR; THORAX PAIN; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; THROMBOCYTOPOIESIS;

EID: 41349111682     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.002     Document Type: Review

References (90)

1. Cines DB, Bussel JB, McMillan RB, et al. Congenital and acquired thrombocytopenia. Hematology Am Soc Hematol Educ Program 2004; 390-406.
2. McMillan R. Classical management of refractory adult immune (idiopathic) thrombocytopenic purpura. Blood Rev 2002; 16:51-5.
3. McMillan R, Wang L, Tomer A, et al. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood 2004; 103:1364-9.
4. Chang M, Nakagawa PA, Williams SA, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102:887-95.
5. van der Wall E, Beijnen JH, Rodenhuis S. High-dose chemotherapy regimens for solid tumors. Cancer Treat Rev 1995; 21:105-32.
6. Frei E III, Teicher BA, Holden SA, et al. Preclinical studies and clinical correlation of the effect of alkylating dose. Cancer Res 1988; 48:6417-23.
7. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003; 21:3423-30.
8. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21:317-21.
9. Leyvraz S, Herrmann R, Guillou L, et al. Treatment of advanced soft-tissue sarcomas using a combined strategy of high-dose ifosfamide, high-dose doxorubicin and salvage therapies. Br J Cancer 2006; 95:1342-7.
10. Cairo MS, Shen V, Krailo MD, et al. Prospective randomized trial between two doses of granulocyte colony-stimulating factor after ifosfamide, carboplatin, and etoposide in children with recurrent or refractory solid tumors: a Children's Cancer Group report. J Pediatr Hematol Oncol 2001; 23:30-8.
11. Niitsu N, Okamoto M, Tomita N, et al. Multicentre phase II study of the baseline BEACOPP regimen for patients with advanced-stage Hodgkin's lymphoma. Leuk Lymphoma 2006; 47:1908-14.
12. Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 1998; 16:642-50.
13. Womer RB, Daller RT, Fenton JG, et al. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000; 36:87-94.
14. Sung L, Nathan PC, Lange B, et al. Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. J Clin Oncol 2004; 22:3350-6
15. Rosen LS, Abdi E, Davis ID, et al. Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 2006; 24:5194-200.
16. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 2004; 351:2590-8.
17. Csáki C, Ferencz T, Schuler D, et al. Recombinant human erythropoietin in the prevention of chemotherapy-induced anaemia in children with malignant solid tumours. Eur J Cancer 1998; 34:364-7.
18. Stemmler HJ, Kahlert S, Brudler O, et al. High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study. Clin Oncol (R Coll Radiol) 2005; 17:630-5.
19. Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995; 13:2796-804.
20. Panzer S, Seel E, Brunner M, et al. Platelet autoantibodies are common in hepatitis C infection, irrespective of the presence of thrombocytopenia. Eur J Haematol 2006; 77:513-7.
21. Collantes RS, Younossi ZM. The use of growth factors to manage the hematologic side effects of PEG-interferon alfa and ribavirin. J Clin Gastroenterol 2005; 39(1 suppl):S9-13.
22. Kowdley KV. Hematologic side effects of interferon and ribavirin therapy. J Clin Gastroenterol 2005; 39(1 suppl):S3-8.
23. Kuter DJ. Thrombopoietin: biology and clinical applications. Oncologist 1996; 1:98-106.
24. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100:3457-69.
25. Wendling F. Thrombopoietin: its role from early hematopoiesis to platelet production. Haematologica 1999; 84:158-66.
26. Deutsch VR, Tomer A. Megakaryocyte development and platelet production. Br J Haematol 2006; 134:453-66.
27. Ninos JM, Jefferies LC, Cogle CR, et al. The thrombopoietin receptor, c-Mpl, is a selective surface marker for human hematopoietic stem cells. J Transl Med 2006; 4:9.
28. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005; 115:3339-47.
29. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996; 87:2154-61.
30. Ensembl gene report for ENSG00000090534. Ensembl Human GeneView Web site. Available at: http://www.ensembl.org/Homo_sapiens/geneview?gene= ENSG00000090534. Accessed: February 28, 2008.
31. Kaushansky K, Drachman JG. The molecular and cellular biology of thrombopoietin: the primary regulator of platelet production. Oncogene 2002; 21:3359-67.
32. Kaushansky K. Lineage-specific hematopoietic growth factors. N Engl J Med 2006; 354:2034-45.
33. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer [published correction appears in Blood 1997; 90:2513]. Blood 1997; 89:3118-28.
34. Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94:3694-701.
35. Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 2000; 18:2852-61.
36. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000; 95:2530-5.
37. Geissler K, Yin JA, Ganser A, et al. Prior and concurrent administration of recombinant human megakaryocyte growth and development factor in patients receiving consolidation chemotherapy for de novo acute myeloid leukemia - a randomized, placebo-controlled, double-blind safety and efficacy study. Ann Hematol 2003; 82:677-83.
38. Crawford J, Glaspy J, Belani C, et al. A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy. Proc Am Soc Clin Oncol 1998; 17:73a (Abstract 285).
39. Cripe L, Neuber D, Tallman M, et al. A pilot study of recombinant human thrombopoietin (rh-TPO) and GM-CSF following induction therapy in patients older than 55 years with acute myeloid leukemia (AML). Blood 1998; 92:(Absttact 2359).
40. Vadhan-Raj S, Verschraegen CF, Bueso-Ramos C, et al. Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer. Ann Intern Med 2000; 132:364-8.
41. Angiolillo AL, Davenport V, Bonilla MA, et al. A phase I clinical, pharmacologic, and biologic study of thrombopoietin and granulocyte colony-stimulating factor in children receiving ifosfamide, carboplatin, and etoposide chemotherapy for recurrent or refractory solid tumors: a Children's Oncology Group experience. Clin Cancer Res 2005; 11:2644-50.
42. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycolconjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997; 336:404-9.
43. Vadhan-Raj S, Patel S, Bueso-Ramos C, et al. Importance of predosing of recombinant human thrombopoietin to reduce chemotherapy-induced early thromobocytopenia. J Clin Oncol 2003; 21:3158-67.
44. Tijssen MR, van der Schoot CE, Voermans C, et al. Clinical approaches involving thrombopoietin to shorten the period of thrombocytopenia after high-dose chemotherapy. Transfus Med Rev 2006; 20:283-93.
45. Kuter DJ. Whatever happened to thrombopoietin? Transfusion 2002; 42:279-83.
46. Avecilla ST, Hattori K, Heissig B, et al. Chemokine-mediated interaction of hematopoietic progenitors with the bone marrow vascular niche is required for thrombopoiesis. Nat Med 2004; 10:64-71.
47. Nomura S, Dan K, Hotta T, et al. Effects of pegylated recombinant human megakaryocyte growth and development factor in patients with idiopathic thrombocytopenic purpura. Blood 2002; 100:728-30.
48. Rice L, Nichol JL, McMillan R, et al. Cyclic immune thrombocytopenia responsive to thrombopoietic growth factor therapy. Am J Hematol 2001; 68:210-4.
49. Hua B, Zou N, Wang S, et al. Multiple cycles of recombinant human thrombopoietin therapy in a patient with chronic refractory idiopathic thrombocytopenic purpura. Blood Coagul Fibrinolysis 2005; 16:291-5.
50. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98:3241-8.
51. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002; 99:2599-602.
52. Wagner LM, Furman WL. Haemopoietic growth factors in paediatric oncology: a review of the literature. Paediatr Drugs 2001; 3:195-217.
53. Rice L. Drug evaluation: AMG-531 for the treatment of thrombocytopenias. Curr Opin Investig Drugs 2006; 7:834-41.
54. Nichol JL. AMG 531: an investigational thrombopoiesis-stimulating peptibody. Pediatr Blood Cancer 2006; 47(5 suppl):723-5.
55. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76:628-38.
56. Newland A, Caulier MT, Kappers-Klunne M, et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135:547-53.
57. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP [published correction appears in N Engl J Med 2006; 355:2054]. N Engl J Med 2006; 355:1672-81.
58. Bussel JB, Kuter DJ, George JN, et al. Long-term dosing of AMG 531 is effective and well tolerated in thrombocytopenic patients with immune thrombocytopenic purpura. Blood 2005; 106:68a (Abstract 220).
59. Kuter D, Bussel JB, George J, et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Blood 2006; 108:144a (Abstract 476).
60. Douglas VK, Tallman MS, Cripe LD, et al. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. Am J Clin Pathol 2002; 117:844-50.
61. Mufti G, Bagg A, Hasserjian R, et al. Bone marrow reticulin in patients with immune thrombocytopenic purpura. Blood 2006; 108:73a (Abstract 3982).
62. Stepan DE, Sergis-Deavenport E, Kelly R, et al. Safety profile of AMG 531 in healthy volunteers and in thrombocytopenic patients with immune thromobocytopenic purpura. Blood 2005; 106:361a (Abstract 1240).
63. ClinicalTrials.gov Web site. Available at: http://clinicaltrials.gov. Accessed: February 28, 2008.
64. Luengo JI, Duffy KJ, Shaw AN, et al. Discovery of SB-497115, a small-molecule thrombopoietin (TPO) receptor agonist for the treatment of thrombocytopenia. Blood 2004; 104:795a (Abstract 2910).
65. Jenkins JM, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. Blood 2007; 109:4739-41.
66. Bussel JB, Cheng G, Saleh M, et al. Eltrombopag for treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007; 357:2237-47.
67. Provan D, Saleh D, Goodison S, et al. The safety profile of eltrombopag, a novel, oral platelet growth factor, in thrombocytopenic patients and healthy subjects. J Clin Oncol 2006; 24(18 suppl):695s (Abstract 18596).
68. Bussel JB, Provan A, Shamsi T, et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a phase III study. Haematologica 2007; 92(suppl 2):143 (Abstract 0390).
69. McHutchison JG, Dusheiko G, Shiffman ML, et al. Eltrombopag for thrombocytopenia in patients with cirrhoisis associated with hepatitis C. N Engl J Med 2007; 357:2227-36.
70. Su S-F, Peng B, Williams D, et al. A phase I study to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of an oral platelet growth factor (SB-559448) in healthy subjects. Blood 2006; 108:319a (Abstract 1072).
71. Suzuki K, Abe M, Fukushima-Shintani M, et al. YM477, a novel orally-active thrombopoietin receptor agonist. Blood 2005; 106:647a (Abstract 2298).
72. Desjardins RE, Tempel DL, Lucek R, et al. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood 2006; 108:145a (Abstract 477).
73. Thrombocytopenia: AKR-501 (YM477). AkaRx Web site. Available at: http://www.akarx.com/pipeline/default.htm. Accessed: February 28, 2008.
74. Dziewanowska ZE, Matsumoto RM, Zhang JK, et al. Single and multiple oral doses of LGD-4665, a small molecule thrombopoietin receptor agonist, increase platelet counts in healthy male subjects. Blood 2007; 110:390a (Abstract 1298).
75. Nakamura T, Miyakawa Y, Miyamura A, et al. A novel nonpeptidyl human c-Mpl activator stimulates human megakaryopoiesis and thrombopoiesis. Blood 2006; 107:4300-7.
76. Yamane A, Nakamura,T, Ito M, et al. Prevention of human interferon-alpha-induced thrombocytopenia by a non-peptidyl human thrombopoietin receptor activator, NIP-004. Blood 2006; 108:339a (Abstract 1145).
77. Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997; 89:3897-908.
78. FDA oncology tools product label details in conventional order for oprelvekin. Food and Drug Administration Web site. Available at: http://www.accessdata.fda.gov/scripts/cder/onctools/labels.cfm?GN=Oprelvekin. Accessed: February 28, 2008.
79. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997; 15:3368-77.
80. Tepler I, Elias L, Smith JW II, et al. A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy. Blood 1996; 87:3607-14.
81. Montero AJ, Estrov Z, Freireich EJ, et al. Phase II study of low-dose interleukin-11 in patients with myelodysplastic syndrome. Leuk Lymphoma 2006; 47:2049-54.
82. Ghalib R, Levine C, Hassan M, et al. Recombinant human interleukin-11 improves thrombocytopenia in patients with cirrhosis. Hepatology 2003; 37:1165-71.
83. Bussel JB, Mukherjee R, Stone AJ. A pilot study of rhuIL-11 treatment of refractory ITP. Am J Hematol 2001; 66:172-7.
84. Corazza F, Hermans C, D'Hondt S, et al. Circulating thrombopoietin as an in vivo growth factor for blast cells in acute myeloid leukemia. Blood 2006; 107:2525-30.
85. Romanelli RG, Petrai I, Robino G, et al. Thrombopoietin stimulates migration and activates multiple signaling pathways in hepatoblastoma cells. Am J Physiol Gastrointest Liver Physiol 2006; 290:G120-8.
86. Komura E, Matsumura T, Kato T, et al. Thrombopoietin in patients with hepatoblastoma. Stem Cells 1998; 16:329-33.
87. Bennett CL, Evens AM, Andritsos LA, et al. Haematological malignancies developing in previously healthy individuals who received haematopoietic growth factors: report from the Research on Adverse Drug Events and Reports (RADAR) project. Br J Haematol 2006; 135:642-50.
88. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362:1255-60.
89. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005; 23:5960-72.
90. FDA public health advisory: erythropoiesis-stimulating agents (ESAs). Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/ drug/advisory/RHE2007.htm. Accessed: February 28, 2008.